A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma

Journal of Gastrointestinal Cancer

Volumn 42, Issue 3, 2011, Pages 160-164

  Lowery, Maeve ^a   Shah, Manish A ^a   Smyth, Elizabeth ^a   Epstein, Andrew ^a   Segal, Amiel ^b   Rosengarten, Ora ^b   Isacson, Rut ^b   Drukker, Lior ^b   Keinan, Anner ^b   Rachkiman, Meir ^b   Reissman, Petachae ^b   Gabizon, Alberto ^b   Kelsen, David ^a   O'Reilly, Eileen M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

BRCA 1; BRCA 2; Hereditary pancreatic cancer; Pancreatic adenocarcinoma; PARP inhibitor; Poly ADP ribose inhibitor

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 19-9 ANTIGEN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OLAPARIB; OXALIPLATIN; STEROID; TAMOXIFEN;

AGED; ANGIOSARCOMA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DRUG HYPERSENSITIVITY; DYSPNEA; EPIGASTRIC DISCOMFORT; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; JEW; LIVER BIOPSY; LIVER METASTASIS; ONCOGENE; OXYGEN SATURATION; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SKIN TEST; STEROID THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CISPLATIN; DEOXYCYTIDINE; FEMALE; GERM-LINE MUTATION; HUMANS; MITOMYCIN; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 80055004748     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-010-9197-1     Document Type: Article

References (16)

1. Sweeney A, Fisher W, Wu M-F, et al. Value of pancreatic resection for cancer metastatic to the pancreas. J Surg Res. 2010;160:268-76.
2. Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol. 1983;23:175-80. (Pubitemid 13035296)
3. Cancer risks in BRCA2 mutation carriers. The breast cancer linkage consortium. J Natl Cancer Inst. 1999;91:1310-6.
4. Brose M, Rebbeck T, Calzone K, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94:1365-72. (Pubitemid 35154141)
5. Hahn S, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003;95:214-21. (Pubitemid 36240634)
6. Couch F, Johnson M, Rabe K, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomark Prev. 2007;16:342-6. (Pubitemid 46383356)
7. Klein A, Brune K, Petersen G, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64:2634-8. (Pubitemid 38523922)
8. Pogue-Geile KL, Chen R, Bronner MP, et al. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med. 2006;3:e516.
9. Klein A, Borges M, Griffith M, et al. Absence of deleterious palladin mutations in patients with familial pancreatic cancer. Cancer Epidemiol Biomark Prev. 2009;18:1328-30.
10. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol: Mech Dis. 2008;3:157-88. (Pubitemid 351488279)
11. McCabe N, Lord C, Tutt ANJ, et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther. 2005;4:934-6. (Pubitemid 41598586)
12. Siu SWK, Chan RTT, Au GKH. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol. 2006;17:259-61. (Pubitemid 43160115)
13. de Vries R, Mattijssen E, van Sorge A. Serious delayed hypersensitivity reaction to oxaliplatin. Ann Oncol. 2006;17:1723-4. (Pubitemid 44680899)
14. van der Heijden M, Brody J, Dezentje D, et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res. 2005;11:7508-15. (Pubitemid 41507712)
15. Chalasani P, Kurtin S, Dragovich T. Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation. JOP J Pancreas. 2008;9:305-8. (Pubitemid 351864891)
16. Hudson KL, Holohan MK, Collins FS. Keeping pace with the times-The Genetic Information Nondiscrimination Act of 2008. N Engl J Med. 2008;358:2661-3. (Pubitemid 351860857)